• About
  • Meet The Team
  • Privacy Policy
Thursday, January 28, 2021

Stocks Telegraph
  • Login
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers
No Result
View All Result
Stocks Telegraph
No Result
View All Result

Aimmune Therapeutics [NASDAQ: AIMT] Signs Definitive Agreement With Nestle

Nestle To Acquire Aimmue Therapeutices For $2.6 billion

by Hasnain R
August 31, 2020
in Featured, Investing
Share on FacebookShare on Twitter

Aimmune Therapeutics, Inc. [NASDAQ: AIMT] disclosed today it has signed a definitive agreement with a wholly-owned subsidiary of Nestle S.A, Sociétés des Produits Nestlé S.A.  Sociétés des Produits Nestlé S.A to purchase Aimmune for $34.50 per share in an all-cash transaction representing the total equity value of $2.6 billion, as per the agreement.

All the members of the board of directors of Aimmune were agreed to the agreement. Through this acquisition, both the firms will be able to create a world leader in food allergy prevention and treatment. Aimmune Therapeutics and Nestle S.A both aimed to change the lives of people around the world living with food allergies.

Aimmune Therapeutic traded up 171.03% at $34.15 during the pre-market trading session after its agreement with Nestle S.A. AIMT had a trading volume of 1.89 million as compared to the average volume of 1.11 million.

It has earlier closed at $12.60 and up 5.09% during its last trading session of Friday. It has recorded the day low range of $11.82 and a day high range of $12.68.

In the past 52-weeks of trading, this company’s stock has fluctuated between the low of $10.09 and a high of $37.00. Aimmune moved up 24.88% and moved down -65.95% from its 52-weeks low and high. Focusing on its profitability, its return on assets (ROA) is -92.70%, and return on equity (ROE) is -170.90%.

Turing our focus on its liquidity, it has a current ratio of 7.50 and its quick ratio is 7.40. Aimmune Therapeutics has a total market capitalization of 784.73 million. It has reported the sales of 0.60 million.

Until the completion of the transaction, Aimmune will work as an independent firm. Looking at the transaction details, Nestle S.A will start a tender offer to buy all the outstanding shares of AIMT. After the completion of the tender offer, Nestle will start the merger of Aimmune with a subsidiary of SPN.

PALFORZIA of Aimmune is the first official treatment for peanut allergy. Palforiza is the first health product which has significant sale potential. The deal between Aimmune and SPN is anticipated to conclude in the fourth quarter of 2020.

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

Tags: Aimmune Therapeutics IncAIMT stockMergerNASDAQ: AIMTNestlePALFORZIASociétés des Produits Nestlé S.A

Related Posts

Is NIO Limited (NYSE: NIO) A Good Option Right Now?
Investing

The 3 Best Chinese EV Stocks in the stock market to buy

January 28, 2021
The Best 3 Food Delivery Stocks for long-term Investment
Investing

The Best 3 Food Delivery Stocks for long-term Investment

January 27, 2021
Stocks to Watch as Fears of a Renewed China/U.S Trade War Dampens Markets
Investing

Edesa Biotech (EDSA) Stock Losing Today After A Significant Rally In Previous Session

January 27, 2021
9 Trending Stocks in Travel Services Industry That Can Be A Good Bets
Investing

Vertex Energy (VTNR) Stock Losing Today, But Might Achieve NASDAQ Listing Criteria This Week

January 27, 2021
Top Performing Stocks Even as Weak Private Payrolls Data Dampens Market Sentiment
Investing

Express (EXPR) Speeds Up liquidity with $140 million additional financing

January 27, 2021
Tesla Inc. (NASDAQ: TSLA) Reportedly Discuss Nickel Supply Deal With Top Miner BHP
Featured

AMC Entertainment (AMC) Avoids Bankruptcy as Shares Pop Up

January 27, 2021
Next Post
Eastman Kodak [KODK] Leads the List of Stock Biggest Gainers Even as Market Sentiment Remains Sluggish

Stocks to watch as Market Sentiment Turns Positive Amidst a Drop in Uncertainty

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

BlackBerry Ltd. (BB) on a roll; the potential of BB Stock in 2021

Stocks to Watch amidst Mixed Market Sentiment after Fed Policy Framework
by Ali Hassan
January 25, 2021
0

BlackBerry stock has nearly tripled since the first week of January and continues to push further. BlackBerry Ltd. (BB) has...

Read more

GameStop (GME) Stock Continues to Spike Days after the Appointment of Ryan Cohen

Top Performers Markets Awaits News from Congress and the Federal Reserve
by Ali Hassan
January 22, 2021
0

Is the bull run going to end anytime soon, or should you invest in GME now? Investors are having a...

Read more

Looking for $1 Stock? BIOLASE (BIOL) is a Decent Bet

by Ali Hassan
January 21, 2021
0

The dental device firm is bullish and looks solid for long-term growth. The medical device firm, BIOLASE Inc. (BIOL) had...

Read more

Why Castor Maritime (CTRM) Stock Is Falling Today

Top Gainers Pre-Market as Big Tech Uplifts Markets
by Shan Zee
January 27, 2021
0

The dry bulk vessels-focused marine shipping company Castor Maritime Inc. (CTRM) has seen its stock price falling -10.35% to $0.350...

Read more

Koss Corp. (KOSS) Stock touches new 52-week High in Premarket

by Shan Zee
January 26, 2021
0

Koss stock is soaring over 76% from the prior close at $6. Some serious bulls are pushing the stock to...

Read more
  • About
  • Meet The Team
  • Privacy Policy

© 2020 Stocks Telegraph - All Rights Reserved

No Result
View All Result
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers

© 2020 Stocks Telegraph - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.